Bristol-Myers Squibb
3Q Revenues: $5.1 billion (+22%)
3Q Earnings: $858 million (+154%)
YTD Revenues: $14.5 billion (+5%)
YTD Earnings: $2.3 billion (+35%)
Comments: Earnings for 3Q07 were boosted by $247 million from the sell-off of the Bufferin and Excedrin brands in Japan. Worldwide pharma sales grew 24% to $3.9 billion, but that growth rate is affected by the 3Q06 sales of generic Plavix by Apotex. The company estimated that the generic competitor sapped $525-$600 million from 3Q06 sales. Plavix sales in the U.S. were up 128% to $1.1 billion. Sales of schizophrenia/bipoolar treatment Abilify grew 34% to $420 million worldwide.
Magazine
